YARW SCHEDULE 13D/A: SEC filing

Yarrow Bioscience, Inc.

Filed with the SEC on · accession 0001193125-26-470747

Yarrow Bioscience, Inc. (YARW) filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 20, 2026. AI Biotechnology LLC and affiliated reporting persons (Access Industries entities and Len Blavatnik) filed Amendment No. 2 to their Schedule 13D reporting beneficial ownership of approximately 1.16% of Yarrow Bioscience's common stock, including 22,331 shares held directly and 155,848 shares… The stock moved -9.3% by the first close after the filing.

Summary of the filing

AI Biotechnology LLC and affiliated reporting persons (Access Industries entities and Len Blavatnik) filed Amendment No. 2 to their Schedule 13D reporting beneficial ownership of approximately 1.16% of Yarrow Bioscience's common stock, including 22,331 shares held directly and 155,848 shares issuable upon exercise of pre-funded warrants.

Key details

Shares of common stock held directly by AI Biotechnology$22K
Shares issuable upon exercise of pre-funded warrants$156K
Total beneficial ownership$178K
Shares outstanding as of November 3, 2026$15.2M
Reporting person / direct holder of shares and warrantsAI Biotechnology LLC
Reporting person / affiliateAccess Industries Holdings LLC
Reporting person / affiliateAccess Industries Management, LLC
Issuer / subject companyYarrow Bioscience, Inc.
Reporting person / beneficial ownerLen Blavatnik

How YARW stock reacted

Close before

$14.23

Nov 19, 2026

First close after

-9.35%

$12.90

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for YARW, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for YARW?

Click here

Frequently asked questions

What did YARW file with the SEC on Nov 20, 2026?

YARW filed a SCHEDULE 13D/A (SEC filing). AI Biotechnology LLC and affiliated reporting persons (Access Industries entities and Len Blavatnik) filed Amendment No. 2 to their Schedule 13D reporting beneficial ownership of approximately 1.16% of Yarrow Bioscience's common stock, including 22,331 shares held directly and 155,848 shares issuable upon exercise of pre-funded warrants.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did YARW stock react to this filing?

YARW closed at $14.23 before the filing and $12.90 on Nov 20, 2026 (-9.35%).

Other YARW SEC filings

Get alerts when YARW files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days